Gavin Clark-Gartner
Stock Analyst at Evercore ISI
(4.90)
# 259
Out of 5,104 analysts
239
Total ratings
61.2%
Success rate
33.8%
Average return
Main Sectors:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Reiterated: Hold | $78 → $127 | $122.85 | +3.38% | 2 | Oct 30, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $26 | $29.06 | -10.51% | 13 | Oct 30, 2026 | |
| FHTX Foghorn Therapeutics | Downgraded: Hold | $14 → $3 | $2.10 | +42.86% | 4 | Oct 13, 2026 | |
| MIRM Mirum Pharmaceuticals | Reiterated: Buy | $138 → $146 | $96.97 | +50.56% | 20 | Oct 13, 2026 | |
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $65 → $70 | $49.04 | +42.74% | 2 | Oct 13, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,059 → $1,078 | $931.38 | +15.74% | 14 | Oct 9, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Hold | $16 → $18 | $17.16 | +4.90% | 7 | Sep 21, 2026 | |
| ABBV AbbVie | Rated: Buy | $235 → $260 | $294.83 | -11.81% | 18 | Aug 10, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $21 | $8.60 | +144.19% | 6 | Aug 10, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | $120 → $134 | $85.81 | +56.16% | 10 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 → $22 | $6.04 | +264.24% | 4 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 | $18.99 | +0.05% | 28 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $39 → $5 | $1.81 | +176.24% | 2 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 → $78 | $52.42 | +48.80% | 9 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $329 | $257.93 | +27.55% | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $162 → $170 | $110.00 | +54.55% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $18.54 | +77.99% | 7 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $91 | $31.97 | +184.64% | 8 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.5111 | - | 8 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.90 | - | 7 | Jul 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $27.47 | +85.66% | 1 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $295 → $300 | $310.84 | -3.49% | 14 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $18 | $9.42 | +91.08% | 4 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $46 | $22.94 | +100.52% | 1 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 → $26 | $32.70 | -20.49% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 → $17 | $8.24 | +106.31% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.42 | +181.69% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.41 | +254.61% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $2.61 | +91.57% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4 | $1.07 | +273.83% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.12 | n/a | 1 | May 30, 2023 |
Incyte
Oct 30, 2026
Reiterated: Hold
Price Target: $78 → $127
Current: $122.85
Upside: +3.38%
Viridian Therapeutics
Oct 30, 2026
Reiterated: Buy
Price Target: $26
Current: $29.06
Upside: -10.51%
Foghorn Therapeutics
Oct 13, 2026
Downgraded: Hold
Price Target: $14 → $3
Current: $2.10
Upside: +42.86%
Mirum Pharmaceuticals
Oct 13, 2026
Reiterated: Buy
Price Target: $138 → $146
Current: $96.97
Upside: +50.56%
First Tracks Biotherapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $65 → $70
Current: $49.04
Upside: +42.74%
argenx SE
Oct 9, 2026
Reiterated: Buy
Price Target: $1,059 → $1,078
Current: $931.38
Upside: +15.74%
Ultragenyx Pharmaceutical
Sep 21, 2026
Reiterated: Hold
Price Target: $16 → $18
Current: $17.16
Upside: +4.90%
AbbVie
Aug 10, 2026
Rated: Buy
Price Target: $235 → $260
Current: $294.83
Upside: -11.81%
COMPASS Pathways
Aug 10, 2026
Reiterated: Buy
Price Target: $21
Current: $8.60
Upside: +144.19%
Dianthus Therapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: $120 → $134
Current: $85.81
Upside: +56.16%
Aug 10, 2026
Reiterated: Buy
Price Target: $55 → $22
Current: $6.04
Upside: +264.24%
Aug 10, 2026
Reiterated: Hold
Price Target: $19
Current: $18.99
Upside: +0.05%
Aug 10, 2026
Downgraded: Hold
Price Target: $39 → $5
Current: $1.81
Upside: +176.24%
Aug 10, 2026
Reiterated: Buy
Price Target: $68 → $78
Current: $52.42
Upside: +48.80%
Aug 7, 2026
Reiterated: Buy
Price Target: $329
Current: $257.93
Upside: +27.55%
Aug 7, 2026
Reiterated: Buy
Price Target: $162 → $170
Current: $110.00
Upside: +54.55%
Jul 27, 2026
Reiterated: Buy
Price Target: $33
Current: $18.54
Upside: +77.99%
Jul 9, 2026
Reiterated: Buy
Price Target: $91
Current: $31.97
Upside: +184.64%
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $0.5111
Upside: -
Jul 6, 2026
Rated: Hold
Price Target: n/a
Current: $15.90
Upside: -
May 26, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $27.47
Upside: +85.66%
May 5, 2026
Reiterated: Buy
Price Target: $295 → $300
Current: $310.84
Upside: -3.49%
Apr 1, 2026
Reiterated: Buy
Price Target: $20 → $18
Current: $9.42
Upside: +91.08%
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $46
Current: $22.94
Upside: +100.52%
Mar 2, 2026
Reiterated: Buy
Price Target: $24 → $26
Current: $32.70
Upside: -20.49%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $8 → $17
Current: $8.24
Upside: +106.31%
Dec 17, 2025
Reiterated: Hold
Price Target: $4
Current: $1.42
Upside: +181.69%
Dec 17, 2025
Reiterated: Buy
Price Target: $5
Current: $1.41
Upside: +254.61%
Dec 17, 2025
Reiterated: Hold
Price Target: $5
Current: $2.61
Upside: +91.57%
Dec 17, 2025
Reiterated: Hold
Price Target: $4
Current: $1.07
Upside: +273.83%
May 30, 2023
Reiterated: Buy
Price Target: $10
Current: $3.12
Upside: n/a